Key clinical point: Some chimeric antigen receptor T-cell therapy patients may experience worse mental health after treatment.
Major finding: Seven patients (17.5%) had global mental health scores that were 1 standard deviation lower than the general population mean.
Study details: A patient-reported outcomes study involving 40 patients with relapsed or refractory chronic lymphocytic leukemia, non-Hodgkin lymphoma, or acute lymphoblastic leukemia who had undergone CD19-targeted chimeric antigen receptor T-cell therapy 1-5 years prior.
Disclosures: The study was funded by the National Institutes of Health, Life Science Discovery Fund, Juno Therapeutics/Celgene, and others. The investigators reported additional relationships with Nektar Therapeutics, Allogene Therapeutics, T-CURX, and others.
Ruark J et al. Biol Blood Marrow Transplant. 2019 Oct 9. doi: 10.1016/j.bbmt.2019.09.037.